Health Systems Research Case Studies in East Africa -

Martin C. Were, MD MS Feb 25th, 2011



Regenstrief Medical Informatics

he **Source** for Medical Informatics

Course Title

<u>Health information systems</u> to improve <u>quality of care</u> in <u>resource poor settings</u>.



Definition: Resource Poor Settings

- Economies are divided according to Gross National Income (GNI) per capita.
- Groups are (for 2011):
 - Low income \$995 or less
 - Lower middle income \$996 \$3,945
 - Upper middle income -\$3,946 \$12,195
 - High income \$12,196 or more.

- Country Classification Data | The World Bank



Low-income economies (40)

Afghanistan Bangladesh Benin Burkina Faso Burundi Cambodia Central African Republic Chad Comoros Congo, Dem. Rep Eritrea Ethiopia Gambia, The Ghana

Guinea Guinea-Bisau Haiti Kenya Korea, Dem Rep. Kyrgyz Republic Lao PDR Liberia Madagascar Malawi Mali Mauritania Mozambique Myanmar

Nepal Niger Rwanda Sierra Leone Solomon Islands Somalia Tajikistan Tanzania Togo Uganda Zambia Zimbabwe

- Country Classification Data | The World Bank

Lower-middle-income economies (56)

Angola Armenia Belize Bhutan Bolivia Cameroon Cape Verde China Congo, Rep. Côte d'Ivoire Djibouti Ecuador Egypt, Arab Rep. El Salvador Georgia Guatemala Guyana Honduras Indonesia

India Iraq Jordan Kiribati Kosovo Lesotho Maldives Marshall Islands Micronesia, Fed. Sts. Moldova Mongolia Morocco Nicaragua Nigeria Pakistan Papua New Guinea Paraguay Philippines Samoa

São Tomé and Principe Senegal Sri Lanka Sudan Swaziland Syrian Arab Republic Thailand Timor-Leste Tonga Tunisia Turkmenistan Tuvalu Ukraine Uzbekistan Vanuatu Vietnam West Bank and Gaza Yemen, Rep.



- Country Classification Data | The World Bank

Definition: Quality of Care

"The degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with current professional knowledge."

- Institute of Medicine (IOM)



Elements of Quality Care

- Recognize patients at risk for diseases.
- Do appropriate evaluation.
- Make the appropriate diagnosis.
- Start the appropriate treatment.
- Schedule the appropriate follow-up.
- Stimulate the appropriate adherence to treatment.

- Feld, S: What is the Definition of Quality Medical Care.



Definition: Health IT

"The application of information processing involving both computer hardware and software that deals with the storage, retrieval, sharing, and use of health care information, data, and knowledge for communication and decision making."

- Brailer & Thompson, 2004



Poor QoC in Resource-Poor Settings

- Patients at risk for diseases are not being recognized.
- Patients are not receiving the appropriate evaluation.
- Appropriate diagnoses are not being made.
- Patients are not being started on appropriate treatment.
- Patients not getting appropriate follow-up.



QoC and Resources

- Good quality of care requires financial and human resources.
- Are the current resources being optimally used?



Executive Healthcare Management

European Region

Western Pacific

Eastern Mediterranean

African Region

South East Asian Region

Americas



Global Health Indicators: Are We Better or Worse Off Now?

A recent WHO report reveals some encouraging signs of progress in world related health issues over the past 10–15 years. Despite this, we still have a long way to go...







Immunisation Coverage: Measles Percentage among 1 year olds Births Attended by Health Personnel Percentage Access to Improved Drinking Water Sources











© World Health Organization (WHO). All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/fairuse.

Source: World Health Organisation

Health Expenditure

ЕНМ

Does HIT improve Quality of Care?

OPEN O ACCESS Freely available online

PLOS MEDICINE

The Impact of eHealth on the Quality and Safety of Health Care: A Systematic Overview

Ashly D. Black¹, Josip Car¹, Claudia Pagliari², Chantelle Anandan², Kathrin Cresswell², Tomislav Bokun¹, Brian McKinstry², Rob Procter³, Azeem Majeed⁴, Aziz Sheikh²*

PLoS Med. 2011 Jan 18;8(1):e1000387.

Black A. D., et al. "The Impact of eHealth on the Quality and Safety of Health Care: A Systematic Overview." *D@CG'A YX* 8, no. 1 (2011): e1000387. doi:10.1371/journal.pmed.1000387 CC-BY license 2.5.



eHealth Impact Review

"We found that despite support from policymakers, there was relatively little empirical evidence to substantiate many of the claims made in relation to these technologies. Whether the success of those relatively few solutions identified to improve quality and safety would continue if these were deployed beyond the contexts in which they were originally developed, has yet to be established. Importantly, best practice guidelines in effective development and deployment strategies are lacking."

- Black et al: PLoS Med. 2011 Jan 18;8(1):e1000387.

Black A. D., et al. "The Impact of eHealth on the Quality and Safety of Health Care: A Systematic Overview." *D@cG'A YX* 8, no. 1 (2011): e1000387. doi:10.1371/journal.pmed.1000387 CC-BY license 2.5.



eHealth Impact Review - Conclusion

- There is a large gap between the postulated and empirically demonstrated benefits of eHealth technologies. In addition, there is a lack of robust research on the risks of implementing these technologies and their cost-effectiveness has yet to be demonstrated, despite being frequently promoted by policymakers and ''techno-enthusiasts'' as if this was a given -

- Black et al: PLoS Med. 2011 Jan 18;8(1):e1000387.

Black A. D., et al. "The Impact of eHealth on the Quality and Safety of Health Care: A Systematic Overview." *D@CG'A YX* 8, no. 1 (2011): e1000387. doi:10.1371/journal.pmed.1000387 CC-BY license 2.5.



HIT in resource-poor settings

- Evidence is even more scarce in resource poor countries?
- Could resource-poor countries benefit more from HIT interventions specifically because of they lack resources?
- We need to identify areas where HIT impacts quality of care (and where it does not).
- Impact on process and behavior ≠ Impact on outcomes.
- Need to evaluate the cost-effectiveness of interventions.



Potential Roles of Health IT

- Help in understanding how health systems work.
- Help in improving how health systems work.
- HIT as a direct care intervention.



Understanding how care system works

- What problem are we trying to solve?
- How will the implemented technology impact care processes, experience, and workload?
- Example: WHO and Ugandan MoH wanted to know how EHRs will impact time-use at two HIV clinics.

AIDS Care Vol. 20, No. 6, July 2008, 677–682 Routledge Taylor & Francis Group

Patterns of care in two HIV continuity clinics in Uganda, Africa: a time-motion study

M.C. Were^a*, J.M. Sutherland^b, M. Bwana^c, J. Ssali^d, N. Emenyonu^e, and W.M. Tierney^a



Uganda:



- Population: ~ 33 million
- Life expectancy: M 52 / F 54
- Mortality rate, infant (per 1000 live births) – 84.5
- GNI per capita US \$ 460

Source: CIA World Factbook (public domain image)





© Taylor & Francis. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/fairuse.



Measuring Time Use

- Work Sampling
- Interviews
- Self-Administered Time Sheets
- Patient Flow Analysis Software (e.g. CDC PFA)

• <u>Time & Motion</u>

- Bratt JH et al. A comparison of four approaches for measuring clinician time use. Health Policy & Planning 1999; 14(4): 374-381

- Finkler SA et al. A comparison of Work-Sampling and Time-and-Motion Techniques for Studies in Health Services Research. HSR 1993; 28(5): 576 397 genstrief Medical Informatics

Subjects Observed

- Adult Patients (~ 80 returning pts, 20 new) for each phase of study
- All primary care providers
- Registration / Records Department Staff
- Pharmacy

Only staff working a full-shift were observed, each for 3 full workdays.

Patient and Provider Activities

- 4 days spent at each clinic identifying activities and developing categories.
- Programmed into HanDBase 3[®] software (DDH Software, Inc., Wellington, Florida) on PDAs
- Tested using trained observers.
- Refined accordingly.



Sample Physician Tasks

Activity	Analysis Group
Filing: Putting Documents in Record	Administrative
Talking: Patient / Family	Direct Patient Care
Exam: Pelvic Exam	Direct Patient Care
Reading: Patient Chart	Indirect Patient Care
Writing: On Encounter Form	Indirect Patient Care
Break: Taking Break	Personal
Looking / Waiting: For Patient	Waiting
Walking: Within Clinic	Miscellaneous



Sample Patient Activities

Activity	Analysis Group
Getting: Examined by Doctor	Time With Physician
Getting: Individual Counseling	Time With Other Provider
Getting: ART Medication	Time With Pharmacy
Looking for: Hospital Facility	Miscellaneous
Getting: Registered	Time With Registration
Waiting: For doctor	Waiting for Physician
Waiting: Laboratory	Waiting for Other Provider



Images by MIT OpenCourseWare.



Pre-Implementation Results: PCPs

• Over 140 hours of PCP observation

	Masaka	Mbarara
Mean hrs in Clinic	5.5 ± 1.3 (range 2.5–7.5 h)	4.9 ± 0.95 (range 3.8–6.5 h)
Clinic Start Time	8:56 am - 10:57 am	8:15 am - 9:53 am
Clinic End Time	12:32 pm - 5:21 pm	12:27 pm - 3:35 pm
Pts seen / Day	26 ± 8 (range 16 – 48)	29 ± 7 (range 19 – 41)
Mean pts / hour	3 – 8 patients	4 – 7 patients

Activities of PCPs (% of workday)

Masaka Providers				Mbarara Physicians		
	NP	CO	MD	NP+CO+MD		
Indirect Patient Care	31.3	27.1	32.4	31.2	33.9	
Direct Patient Care	26.2	33.3	27.4	28.2	25.1	
Personal	20.9	15.7	17.9	18.1	16.0	
Administrative	8.2	17.8	16.8	15.0	6.5	
Waiting	7.0	1.4	3.0	3.6	1.4	
Miscellaneous	6.5	4.8	2.6	3.8	17.0	

Image by MIT OpenCourseWare.

Minutes per patient-encounter spent by PCPs

	Minutes per l	p-Value	
	Masaka		
Indirect Patient Care	3.83 (2.84)	3.41 (2.41)	0.04
Direct Patient Care	3.41 (3.09)	2.51 (1.96)	<0.0001

Image by MIT OpenCourseWare.

- Indirect Patient Care: Reading or Writing on patient's chart or encounter form, prescribing medications, discussing patient's care on phone or with other providers.
- **Direct Patient Care**: Talking to or counseling patient(s), and examining or doing a procedure on patient.



Results for Established Patients

• Over 420 hours of patient observation

	Masaka	Mbarara
Daily Patient Census	119 ± 34 (range 71 – 197)	107 ± 45 (range 62 – 172)
Mean Visit Length	77 \pm 38 minutes	196 \pm 84 minutes

Inefficient Systems of Care:

	Mean (median) minutes per visit			
Patient Activity	Masaka	Mbarara		
Waiting	51 (43)	122 (123)		
Time with other staff	11 (5.0)	43 (27)		
Time with clinicians	7.5 (6.3)	8.2 (6.1)		
Miscellaneous	5.8 (3.5)	23 (16)		
Time with pharmacy	2.6 (1.9)	1.7 (1.4)		



Discussion

- PCPs spent a limited amount of time in clinic
- While in clinic 40% of time not spent on tasks related to patient visits
- Some Suggestions:
 - Alleviate other responsibilities outside the clinic.
 - Re-assign tasks so that time is spent on tasks PCPs are uniquely qualified.
 - Re-engineer work processes. Example: Encounter
 Forms vs. Free Text Notes.



Discussion

- Large part of clinic visit spent by patients Waiting.
 - Time & Motion Data gives you information on possible bottlenecks.
- Large variability:
 - In start- and end-times and clinic length for providers
 - In daily patient census.



Discussion

- Need better queue management in this multiple stage system
- Take advantage of the waiting time e.g. to educate and counsel patients
- "Assign responsibility to patient flow problem" Eugene Litvak
- Manage patient daily census better
- Large variability:
 - In start- and end-times and clinic length for providers
 - In daily patient census ? Scheduling system.

Regenstrief Medical Informatics

Impact of EHRs on Time Use



Courtesy of OpenMRS. Used with permission.

OpenMRS Implementations



Overlay courtesy of OpenMRS. Used with permission.

Map © Google. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/fairuse.



EHRs with Clinical Summaries

	ISS	Clinic Patien	nt Summary Sh	heet	
Jane Doe			File Num	iber:	2222-22-222
F 33 (15/06/1975)		ART Number:		ET	
last seen by	(30	/04/2008)			
Diagnosis at la: WHO STAGE 3 TB Status: NO SIGN painful sensory Neu Allergies:	PERIP	ities: HERAL NEUROPA Art Medication		Current ART COMBIVIR NEVIRAPINE Previous AI TRIOMUNE 30	RT Regimen(s)
		VITAL	SIGNS		
	Date	Weight	Temp	BP	K Score
Enrollment	18/10/2007	46	36	84/66	60
ART Start	31/10/2007	46	37	80/60	90
3rd Last visit	13/03/2008	50	35	90/60	90
2nd Last visit	10/04/2008	53	36	120/80	95
Last visit	30/04/2008	53	35	113/76	90
		LAB H	ISTORY		
CD4	Date	HB	Date	Viral load	Date
	18/10/2007	10	23/10/2007		
Results of Mbarara ⁻	Time-Motion S	Study: Provi	ders*		
---------------------------------	---------------	--------------	-------		

Measure	Before	After	Before-After		
	Summaries	Summaries	Difference		
Number of physicians	3	3	0		
Number of clinic hrs/day	6.5	6.4	-0.1		
Number of patients/day	41	44	3		
Direct patient care (%)	25.7	34.6	8.9		
Indirect patient care (%)	35.6	33.2	-2.4		
Administration (%)	6.0	8.8	2.8		
Personal (%)	14.5	13.3	-1.2		
Miscellaneous (%)	16.7	6.6	-10.1		
Waiting (%)	1.4	3.4	2.0		

* Time is measured in percent of a provider's workday. No between group differences were statistically significant (p-value <0.05)

Minutes (mean) spent by providers per patient encounter					
	Before	After			
Activity	Summaries	Summaries	P-Value		
	N = 237	N=395			
Direct patient care ^a	2.3	2.9	< 0.001		
Indirect patient care ^b	3.2	2.9	0.7		

^{*a*} **Direct Patient Care**: Tasks include talking to or counseling patient(s), and examining or doing a procedure on patient.

^b Indirect Patient Care: Tasks include reading clinical summary or patient's chart, writing on encounter form or chart, prescribing medications, discussing patient's care on phone or with other providers.

Were MC, Shen C, Bwana M, Emenyonu N, Musinguzi N, Nkuyahaga F, Kembabazi A, **Tierney WM.** Int J Me^a Inform. 2010;79(2):90-6.

Table 6: Results of Mbarara Time-Motion Study: Patients*				
Measure	Before N = 88	After N = 94	Difference	
Time in registration	1.2	1.0	-0.2	
Time with clinicians	7.7	6.4	-0.7	
Time with other staff	42.3	61.3	+19.0	
Time with pharmacy	1.7	11.6	+9.9	
Miscellaneous activities	22.9	17.9	-5.0	
Waiting	121.9	88.0	-33.9	
Waiting for registration	0.3	0.0	-0.3	
Waiting for clinicians	45.1	44.5	-0.6	
Waiting for other staff	52.4	28.9	- 23.5	
Waiting for pharmacy	24.1	14.6	-9.5	
Total visit time	197.7	186.2	-11.5	

* Time in mins / visit. observed. p-value < 0.05 indicated by shading.



Considerations:

- What implementation models work well to reduce humanresource constraints and cost burden?
- What is the effect of the EHRs on how clinics function?
- Can we assess the impact of these systems on patient care?



Implementation Model



- Were MC, Emenyonu N, Achieng M, Shen C, Ssali J, Masaba JP, Tierney WM. "Evaluating a scalable model for implementing electronic health records in resource-

Clinical Decision Support:

Hypothesis:

EHRs-based reminders to clinicians can improve quality of care, compliance with guidelines, and patient safety in developing countries.

Element of QoC:

Do appropriate evaluation for patients.









Adrian Gardner

Webuye AMPATH Clinic

1. Name: JOHN DOE	AMPATHID: 123MT-2	Previous ID:
2. Location: MTRH Module: X1 12 13 14	3. Category: Pilot	4. Member of
Health Centre:	MTRH Staff DMTCT Staff	Discordant Couple?
☐Mosoriot □Turbo □Burnt Forest		□Yes
□Amukura □Naitiri □Chulaimbo		⊠t No
□Webuye □Kitale □Kapenguria	□Self Pay □Other:	□Unknown
□Teso □Other:	□Awaiting Assignment	
Scheduled Visit Unscheduled Visit	and the state of the	
5. Female Patients:		
5a. Is the patient pregnant? □ Yes _{Weeks} xNo (Go to 5b)	If yes: On ARV-directed pMTCT	「 □Yes □No
5b. Has she delivered since her last visit? DYes Date	e □ No (Go to 6)	
How was the mother treated? □Total pMTCT	DNVP Untreated DOn ARV Th	erapy DUnknown
Infant received NVP? □Yes □No		
		DWaanad
Feeding Method? DBreast DPredominate Brea		uweaned
Baby enrolled in Peds HIV Clinic?		
6. Does the patient have any interval complaints?	?y∰Yes ⊡No	
Comments: HEMOPTYSIS X 3 DA		
REPORTS & SUR	2.5	
7. Current Medications:	- 1.11月1日日本市場の開催時間、第二人が行	
ARVs: X es □No Is this the patient's Primary	rRegimen? ¤ Yes ⊡No	
	Regimen? X Yes □No	
Combivir Triomune-30 Triomune-40	Ň	200 □TDF
□Combivir XTriomune-30 □Triomune-40 □3TC □d4T-30 □d4T-40 □AZT		200 □TDF
□Combivir XTriomune-30 □Triomune-40 □3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir)	200 □TDF
□Combivir XTriomune-30 □Triomune-40 □3TC □d4T-30 □d4T-40 □AZT	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir)	200 □TDF
□Combivir XTriomune-30 □Triomune-40 □3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir)	200 □TDF
□Combivir XTriomune-30 □Triomune-40 □3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: XNone □Septrin □Dapsone TB Prophylaxis: □None XNH	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir)	200 □TDF
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NFV NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None XINH TB Treatment: XNone Rifater (Rifample)	ABC DDI 125 DDI (Lopinavir/Ritonavir)	ır ⊡Ethambutol
□Combivir XTriomune-30 □Triomune-40 □3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: INone □Septrin □Dapsone TB Prophylaxis: □None XINH TB Treatment: XNone □Rifater (Rifamp □Streptomycin □Ethizide (Ethar	ABC DDI 125 DDI (Lopinavir/Ritonavir)	ır ⊡Ethambutol
□Combivir XTriomune-30 □Triomune-40 □3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: □None □Septrin □Dapsone TB Prophylaxis: □None XINH TB Treatment: XNone □Rifater (Rifamp □Streptomycin □Ethizide (Ethar Cryptococcus Tx: XNone □Diflucan	ABC DDI 125 DDI (Lopinavir/Ritonavir)	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None XINH TB Treatment: None Rifater (Rifamp Streptomycin Ethizide (Ethar Cryptococcus Tx: None Diflucan Other Drugs: Other Drugs:	ABC DDI 125 DDI (Lopinavir/Ritonavir)	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None MINH TB Treatment: None Rifater (Rifamp Streptomycin Ethizide (Ethar Cryptococcus Tx: None Diflucan Other Drugs: 8. Adherence:	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) e picin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None XINH TB Treatment: None Rifater (Rifamp Streptomycin Ethizide (Ethar Cryptococcus Tx: None Diflucan Other Drugs: 8. Adherence: During the last month has the patient missed any	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) e picin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB y medications? □Yes XNo	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None MINH TB Treatment: None Rifater (Rifamp Streptomycin Ethizide (Ethar Cryptococcus Tx: None Diflucan Other Drugs: 8. Adherence:	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) e picin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB y medications? □Yes XNo	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None MH TB Treatment: None Rifater (Rifamp Streptomycin Ethizide (Ethar Cryptococcus Tx: None Diflucan Other Drugs: 8. Adherence: During the last month has the patient missed any ARVS PCP Prophylaxis Drugs Missed: TB Prophylaxis TB Prophylaxis	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) e Dicin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB y medications? □Yes ♥No xis □Anti-TB Medication Reason(s):	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None INH Streptomycin Ethizide (Ethar Cryptococcus Tx: XNone Diflucan Other Drugs: Statement: 8. Adherence: During the last month has the patient missed any ARVS PCP Prophylaxis TB Prophylaxis	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) e Dicin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB y medications? □Yes ♥No xis □Anti-TB Medication Reason(s):	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None MH TB Treatment: None Rifater (Rifamp Streptomycin Ethizide (Ethar Cryptococcus Tx: None Diflucan Other Drugs: Statement Septrophylaxis TB Prophyla 8. Adherence: During the last month has the patient missed and and and and and and and and and an	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) e bicin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB weedications? □Yes No xis □Anti-TB Medication Reason(s): pills did the patient take?	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None MH TB Treatment: None Rifater (Rifamp Streptomycin Ethizide (Ethar Cryptococcus Tx: None Diflucan Other Drugs: Adherence: During the last month has the patient missed any ARVS PCP Prophylaxis TB Prophyla During the last seven days how many of his/her Daring the last seven days how many of his/her DARVS: Day None Few	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) a bicin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB a bicin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB a bicin/Pyrazinamide/INH) □Rifafou mbutol/INH) □Rifafou mbuto	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None XINH TB Treatment: None Rifater (Rifamp Streptomycin Ethizide (Ethar Cryptococcus Tx: None Diflucan Other Drugs: S. 8. Adherence: Adherence: During the last month has the patient missed any ARVS PCP Prophylaxis TB Prophyla Mone Few Half M PCP Prophylaxis: None Few Half	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) e bicin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB y medications? □Yes No xis □Anti-TB Medication Reason(s): pills did the patient take? lost □All Drug(s) missed lost □All Drug(s) missed	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None Septrin Dapsone TB Prophylaxis: None Septrin Dapsone TB Treatment: None Siteptomycin Ethizide (Ethar Cryptococcus Tx: Xone Diflucan Other Drugs: 8. Adherence: During the last month has the patient missed any ARVS PCP Prophylaxis TB Prophyla During the last seven days how many of his/her ARVS: Denone Few Half M PCP Prophylaxis: None Few Half M TB Prophylaxis: None Few Half M	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) bicin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB y medications? □Yes KNo xis □Anti-TB Medication Reason(s): pills did the patient take? lost □All □rug(s) missed lost □All □rug(s) missed lost □All □rug(s) missed	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None XINH T TB Treatment: XNone Rifater (Rifamp Streptomycin Ethizide (Ethar Cryptococcus Tx: XNone Diflucan Other Drugs: XNone Diflucan Adherence: XNone Diflucan During the last month has the patient missed any ARVS PCP Prophylaxis During the last seven days how many of his/her ARVS: Drophylaxis During the last seven days how many of his/her ARVS: None During the last seven days how many of his/her ARVS: Drophylaxis: During the last seven days how many of his/her ARVS: Drophylaxis: During the last seven days how many of his/her ARVS: Drophylaxis: During the last seven days how many of his/her ARVS: Half Drugs Missed: None Few Half TB Prophylaxis: Non	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) a bicin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB y medications? □Yes KNo xis □Anti-TB Medication Reason(s): pills did the patient take? lost □All □rug(s) missed lost □All □rug(s) missed lost □All □rug(s) missed	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None XINH TB Treatment: XNone Rifater (Rifamp Streptomycin Ethizide (Ethar Cryptococcus Tx: XNone Diflucan Other Drugs: XNone Diflucan Adherence: XNone Diflucan During the last month has the patient missed any ARVS PCP Prophylaxis ARVS PCP Prophylaxis TB Prophyla ARVS: Deven days how many of his/her ARVS: None Few During the last seven days how many of his/her ARVS: Deven prophylaxis: None Few Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her Maif ARVS: None Few Dring the last seven days how many of his/her Maif ARVS: None Few Half <	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) a bicin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB y medications? □Yes KNo xis □Anti-TB Medication Reason(s): pills did the patient take? lost □All □rug(s) missed lost □All □rug(s) missed lost □All □rug(s) missed	ır ⊡Ethambutol
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None Septrin Dapsone TB Prophylaxis: None Septrin Dapsone TB Treatment: None Rifater (Rifamp Streptomycin Ethizide (Ethar Cryptococcus Tx: None Diflucan Other Drugs: Adherence: During the last month has the patient missed and ARVS PCP Prophylaxis TB Prophyla During the last seven days how many of his/her ARVS: ARVS: None Few Daring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her Maif ARVS: None Few Dring the last seven days how many of his/her Maif <t< td=""><td>□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) a bicin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB y medications? □Yes KNo xis □Anti-TB Medication Reason(s): pills did the patient take? tost □All Drug(s) missed tost □All Drug(s) missed tost □All Drug(s) missed tost □All Drug(s) missed</td><td>Ir DEthambutol treatment:</td></t<>	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) a bicin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB y medications? □Yes KNo xis □Anti-TB Medication Reason(s): pills did the patient take? tost □All Drug(s) missed tost □All Drug(s) missed tost □All Drug(s) missed tost □All Drug(s) missed	Ir DEthambutol treatment:
Combivir Triomune-30 Triomune-40 3TC d4T-30 d4T-40 AZT EFV NVP NFV Kaletra PCP Prophylaxis: None Septrin Dapsone TB Prophylaxis: None XINH TB Treatment: XNone Rifater (Rifamp Streptomycin Ethizide (Ethar Cryptococcus Tx: XNone Diflucan Other Drugs: XNone Diflucan Adherence: XNone Diflucan During the last month has the patient missed any ARVS PCP Prophylaxis ARVS PCP Prophylaxis TB Prophyla ARVS: Deven days how many of his/her ARVS: None Few During the last seven days how many of his/her ARVS: Deven prophylaxis: None Few Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her Maif ARVS: None Few Dring the last seven days how many of his/her Maif ARVS: None Few Half <	□ABC □DDI 125 □DDI (Lopinavir/Ritonavir) a bicin/Pyrazinamide/INH) □Rifafou mbutol/INH) Start Date of TB y medications? □Yes KNo xis □Anti-TB Medication Reason(s): pills did the patient take? tost □All Drug(s) missed tost □All Drug(s) missed tost □All Drug(s) missed tost □All Drug(s) missed	Ir ⊡Ethambutol treatment:





AMPAIN: Adu		Date:
I. Name: JOHN DOE	AMPATHID: 123MT-2	Previous ID:
2. Location: MTRH Module: X1 12 13 14	3. Category: Pilot	4. Member of
Health Centre:	ØMTRH Staff □MTCT Staff	Discordant Couple?
□Mosoriot □Turbo □Burnt Forest	□NASCOP □Research	⊡Yes
□Amukura □Naitiri □Chulaimbo		⊠t No
□Webuye □Kitale □Kapenguria	□Self Pay □Other:	Unknown
□Teso □Other:	□Awaiting Assignment	
Scheduled Visit Unscheduled Visit 5. Female Patients:		la decisión de la companya de la
5a. Is the patient pregnant? □ Yes	If yes: On ARV-directed pMTC	T ⊡Yes ⊡No
jano (Go to 5b)		
5b. Has she delivered since her last visit? □Yes Da	na □ No (Go to 6)	
How was the mother treated?		nerany ⊡Linknown
	LINE DOMIGATED DOMARY II	loupy contrioun
Infant received NVP? DYes No		
Feeding Method? Breast Predominate Breast	east □Formula □Mixed feeding	UWeaned
Baby enrolled in Peds HIV Clinic? Yes	No	
6. Does the patient have any interval complaints	s? xaYes ⊡No	
Comments: HEMOPTYSIS X 3 DA	• •	
12121 19313 4 30	~ 4 3	
T Constant Mada House and Barris and Street		
7. Current Medications:		
	y Regimen? TorYes ⊡No	
□Combivir XTriomune-30 □Triomune-40		
□Combivir X1 riomune-30 □ I riomune-40 □3TC □d4T-30 □d4T-40 □AZT	DABC DDI 125 DDI	200 □TDF
□3TC □d4T-30 □d4T-40 □AZT		200 □TDF
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra	a (Lopinavir/Ritonavir)	200 □TDF
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: xtNone □Septrin □Dapson	a (Lopinavir/Ritonavir)	200 □TDF
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: ¤(None □Septrin □Dapson TB Prophylaxis: □None ¤(NH	a (Lopinavir/Ritonavir) ne	
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: ¤None □Septrin □Dapson TB Prophylaxis: □None ¤INH TB Treatment: ¤None □Rifater (Rifam	a (Lopinavir/Ritonavir) ne npicin/Pyrazinamide/INH) □Rifafo	ur ⊡Ethambutol
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: ☑None □Septrin □Dapson TB Prophylaxis: □None ☑NH TB Treatment: ☑None □Rifater (Rifam □Streptomycin □Ethizide (Etha	a (Lopinavir/Ritonavir) ne npicin/Pyrazinamide/INH) □Rifafo	ur ⊡Ethambutol
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: ☑None □Septrin □Dapson TB Prophylaxis: □None ☑NH TB Treatment: ☑None □Rifater (Rifam □Streptomycin □Ethizide (Etha Cryptococcus Tx: ☑None □Diflucan	a (Lopinavir/Ritonavir) ne npicin/Pyrazinamide/INH) □Rifafo	ur ⊐Ethambutol
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: ☑None □Septrin □Dapson TB Prophylaxis: □None ☑NH TB Treatment: ☑None ☑Rifater (Rifam □Streptomycin □Ethizide (Etha Cryptococcus Tx: ☑None □Diflucan Other Drugs:	a (Lopinavir/Ritonavir) ne npicin/Pyrazinamide/INH) □Rifafo	ur ⊐Ethambutol
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: □None □Septrin □Dapson TB Prophylaxis: □None ▼INH TB Treatment: ▼None □Rifater (Rifam □Streptomycin □Ethizide (Etha Cryptococcus Tx: ▼None □Diflucan Other Drugs: 8. Adherence:	a (Lopinavir/Ritonavir) ne npicin/Pyrazinamide/INH) □Rifafor ambutol/INH) Start Date of TB	ur ⊐Ethambutol
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: INone □Septrin □Dapson TB Prophylaxis: □None INH TB Treatment: INone IRifater (Rifam □Streptomycin □Ethizide (Etha Cryptococcus Tx: None □Diflucan Other Drugs: 8. Adherence: During the last month has the patient missed ar	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) □Rifafor ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB	ur ⊡Ethambutol
BARVS 044T-30 044T-40 0AZT BEFV 0NVP 0NFV 0Kaletra PCP Prophylaxis: INone 10apson TB Prophylaxis: 0None 10apson TB Treatment: INone IRifater (Rifam Btreptomycin Ethizide (Ethal Cryptococcus Tx: None Diflucan Other Drugs: 8. Adherence: During the last month has the patient missed ar DARVS PCP Prophylaxis TB Prophylaxis	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) □Rifafor ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB	ur ⊐Ethambutol
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: □None □Septrin □Dapson TB Prophylaxis: □None ✓INH TB Treatment: ▼None □Rifater (Rifam □Streptomycin □Ethizide (Ethal Cryptococcus Tx: ▼None □Diflucan Other Drugs: 8. Adherence: □ During the last month has the patient missed ar □ARVS □ PCP Prophylaxis □ TB Prophyla □rugs Missed: □	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) □Rifafor ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB	ur ⊡Ethambutol
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: □None □Septrin □Dapson TB Prophylaxis: □None ☑INH □ TB Treatment: ☑None □Rifater (Rifam □Streptomycin □Ethizide (Etha Cryptococcus Tx: ☑None □Diflucan Other Drugs: 3. 8. Adherence: ☑ During the last month has the patient missed ar □ARVS □ PCP Prophylaxis □ TB Prophyla Drugs Missed: □ During the last seven days how many of his/her	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) □Rifafor ambutol/INH) Start Date of TB ny medications? □Yes XNo axis □Anti-TB Medication Reason(s): r pills did the patient take?	ur ⊐Ethambutol
BARVS DAPC Prophylaxis: TB Prophylaxis: TB Prophylaxis: TB Prophylaxis: DAPC Prophylaxis: <	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) □Rifafor ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB Any medications? □Yes XNo axis □Anti-TB Medication Reason(s): r pills did the patient take? Most □All Drug(s) missed	ur ⊐Ethambutol
BARVS DAPC Prophylaxis: TB Prophylaxis: TB Prophylaxis: TB Prophylaxis: DAPC Prophylaxis: <	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) □Rifafor ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB Any medications? □Yes XNo axis □Anti-TB Medication Reason(s): r pills did the patient take? Most □All Drug(s) missed	ur ⊐Ethambutol
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: □None □Septrin □Dapson TB Prophylaxis: □None ☑INH □ TB Treatment: ☑None □Rifater (Rifam □Streptomycin □Ethizide (Etha Cryptococcus Tx: ☑None □Diflucan Other Drugs: 38. Adherence: ☑ ☑ ☑ ☑ During the last month has the patient missed ar ☑ ☑ ☑ □ARVS □ PCP Prophylaxis □ TB Prophyla □ □ARVS □ PCP Prophylaxis □ TB Prophyla ☑ □ARVS: ☑None □ Few □ Half □ □ PCP Prophylaxis: ☑None □ Few □ Half □	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) □Rifafor ambuto//INH) Start Date of TB ambuto//INH) Start Date of TB ambuto//INH ambuto//INH) Start Date of TB ambuto//INH a	ur ⊐Ethambutol
BARVS PCP Prophylaxis: QNOP NFV Kaletra PCP Prophylaxis: QNone Septrin Dapson TB Prophylaxis: None QINH TB Treatment: QNone Rifater (Rifam Streptomycin Ethizide (Ethal Cryptococcus Tx: QNone Diflucan Other Drugs: B Adherence: During the last month has the patient missed ar Dargs Missed: During the last seven days how many of his/her ARVS: QNone Few PCP Prophylaxis: XNone Few BARVS: QNone Few Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her ARVS: Dring the last seven days how many of his/her <t< td=""><td>a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) □Rifafor ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB ambutol/INH ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB ambutol/INH ambutol/INH) Start Date of TB ambutol/INH ambu</td><td>ur ⊡Ethambutol</td></t<>	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) □Rifafor ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB ambutol/INH ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB ambutol/INH ambutol/INH) Start Date of TB ambutol/INH ambu	ur ⊡Ethambutol
BARVS PCP Prophylaxis: QNOP NFV Kaletra PCP Prophylaxis: QNOR Septrin Dapson TB Prophylaxis: None QINH TB Treatment: None QINH Streptomycin Ethizide (Ethal Cryptococcus Tx: None Diflucan Other Drugs: 8. Adherence: During the last month has the patient missed ar Dargs Missed: During the last seven days how many of his/her DARVS: QNone Few Brey Prophylaxis: None Few Brophylaxis: None Few Brophylaxis: None Few Brophylaxis: None Few Brophylaxis: None Few	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) □Rifafor ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB ambutol/INH ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB ambutol/INH ambutol/INH) Start Date of TB ambutol/INH ambu	ur ⊡Ethambutol
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: □None □Septrin □Dapson TB Prophylaxis: □None ✓INH □ TB Treatment: ✓None □Rifater (Rifam □Streptomycin □Ethizide (Etha Cryptococcus Tx: ✓None □Diflucan Other Drugs: 8. Adherence: □ □ During the last month has the patient missed ar □ARVS □ PCP Prophylaxis □ TB Prophyla □args Missed: □ □ During the last seven days how many of his/her □ARVS: ○None □ARVS: ○None □ Few □ Half □ PCP Prophylaxis: ○None □ Few □ Half □ TB Prophylaxis: ○None □ Few □ Half □ □ Anti-TB Medication: ØNone □ Few □ Half □ □ Anti-TB Medication: ØNone □ Few □ Half □	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) □Rifafor ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB ambutol/INH ambutol/INH) Start Date of TB ambutol/INH) Start Date of TB ambutol/INH ambutol/INH) Start Date of TB ambutol/INH ambu	ur ⊐Ethambutol
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: □None □Septrin □Dapson TB Prophylaxis: □None ✓INH □ TB Treatment: ✓None □Rifater (Rifam □Streptomycin □Ethizide (Etha Cryptococcus Tx: ✓None □Diflucan Other Drugs: 8. 8. Adherence: □ □ □ During the last month has the patient missed ar □ARVS □ PCP Prophylaxis □ TB Prophyla □ TB Prophylaxis: □ □ARVS: □ ○None □Few □ Half □ □ PCP Prophylaxis: ○None □Few □ □ □ TB Prophylaxis: ○None □Few □ Half □ □ Anti-TB Medication: ØNone □Few □ Half □ □ Anti-TB Medication:	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) ©Rifafor ambutol/INH) Start Date of TB Start Date of TB Anti-TB Medication Reason(s): r pills did the patient take? Most ©All Drug(s) missed Most ©All Drug(s) missed Most ©All Drug(s) missed	ur DEthambutol treatment:
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: □None □Septrin □Dapson TB Prophylaxis: □None ✓INH □ TB Treatment: ✓None □Rifater (Rifam □Streptomycin □Ethizide (Etha Cryptococcus Tx: ✓None □Diflucan Other Drugs: 8. Adherence: □ □ During the last month has the patient missed ar □ARVS □ PCP Prophylaxis □ TB Prophyla □rugs Missed: □ □ During the last seven days how many of his/her □ARVS: ○None □ARVS: ○None □ Few □ Half □ PCP Prophylaxis: ○None □ Few □ Half □ TB Prophylaxis: ○None □ Few □ Half □ □ TB Prophylaxis: ○None □ Few □ Half □ □ Anti-TB Medication: ØNone □ Few □ Half □ □ Anti-TB Medication: ØNone □ Few □ Half □ □ Physical Exam: □ □ <t< td=""><td>a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) ©Rifafor ambuto//INH) Start Date of TB Start Date of TB Anti-TB Medication Reason(s): r pills did the patient take? Most ©All Drug(s) missed Most ©All Drug(s) missed</td><td>ur ⊡Ethambutol treatment:</td></t<>	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) ©Rifafor ambuto//INH) Start Date of TB Start Date of TB Anti-TB Medication Reason(s): r pills did the patient take? Most ©All Drug(s) missed Most ©All Drug(s) missed	ur ⊡Ethambutol treatment:
□3TC □d4T-30 □d4T-40 □AZT □EFV □NVP □NFV □Kaletra PCP Prophylaxis: □None □Septrin □Dapson TB Prophylaxis: □None ✓INH □ TB Treatment: ✓None □Rifater (Rifam □Streptomycin □Ethizide (Etha Cryptococcus Tx: ✓None □Diflucan Other Drugs: 8. 8. Adherence: □ □ □ During the last month has the patient missed ar □ARVS □ PCP Prophylaxis □ TB Prophyla □ TB Prophylaxis: □ □ARVS: □ ○None □Few □ Half □ □ PCP Prophylaxis: ○None □Few □ □ □ TB Prophylaxis: ○None □Few □ Half □ □ Anti-TB Medication: ØNone □Few □ Half □ □ Anti-TB Medication:	a (Lopinavir/Ritonavir) ne apicin/Pyrazinamide/INH) ©Rifafor ambutol/INH) Start Date of TB Start Date of TB Anti-TB Medication Reason(s): r pills did the patient take? Most ©All Drug(s) missed Most ©All Drug(s) missed Most ©All Drug(s) missed	ur □Ethambutol treatment:

Elle Edit View Insert Format Tools Table Help Type a question for help Welcomel Academic Model for the Prevention and Treatment of HIV/AIDS in Africa, Page 1/2 Next Page -> 0 0 0 AMPATH: Adult Return Visit Short Form Select a Diagnosis Date: Click -> 🔳 Go AMPATH ID: Previous ID: 1. Name: Last Name: Doe Old IDs only! HINT: type only the first few letters 123MT-2 First Name: John APATHETIC 3. Category: O Pilot 4 Member of ASYMPTOMATIC HIV INFECTION 2. Location: MTRH Module: 1 2 3 4 **Discordant Couple?** Health Centre: DERMATOPHYTOSIS O Mosoriot O Turbo O Burnt Forest DIABETES INSIPIDUS O Yes O NASCOP O MTCT Staff Amukura Naitiri Chulaimbo DYSPEPSIA No O Self Pay O Research O Webuye O Kitale Kapenguria O Unknown FUNGAL INFECTION O Await Assign O Other O Teso GASTROENTERITIS HEAD INJURY Scheduled Visit O Unscheduled Visit HELMINTHIASIS 5. Female Patients: HIV INFECTED 5a. Is the patient pregnant? OYes Weeks If yes: On ARV-directed pMTCT: Yes No HIV STAGING - BACTERIAL INFECTION No (Go to 5b) ■ HIV STAGING - CHILD HSV INFECTION HIV STAGING - INFANT CYTOMEGALOVIRUS 5b. Has she delivered since her last visit? O Yes Date: Click -> I ONo (Go to 6) HIV STAGING - INFANT TOXOPLASMOSIS How was the mother treated? O Total pMTCT O NVP O Untreated O On ARV Therapy O Unknown HIV STAGING - LYMPHOID INTERSTITIAL Infant received NVP? OYes ONo PNELIMONIA HIV STAGING - RECURRENT UPPER Feeding Method? O Breast O Predominate Breast O Formula O Mixed Feeding O Weaned RESPIRATORY INFECTION Baby enrolled in Peds HIV Clinic? OYes ONo HIV STAGING - SERIOUS BACTERIAL INFECTIONS 6. Does the patient have any interval complaints? • Yes ONo HIV STAGING - SEVERE BACTERIAL Comments: INFECTION INFILTRATE 7. Current Medications: INJECTED CONJUCTIVA ARVs: OYes ONo Is this the patient's primary regimen? OYes ONo IN JURY Combivir I Triomune-30 Triomune-40 INSOMNIA □ 3TC □ d4T-30 □ d4T-40 □ AZT □ ABC □ DDI 125 □ DDI 200 □ TDF MISSED ABORTION EFV NVP NFV Kaletra (Lopinavir / Ritonavir) NEONATAL SEPSIS PELVIC INFLAMMATORY DISEASE PCP Prophylaxis: None Septrin O Dapsone POLIOMYELITIS PREGNANCY, HYPERTENSION TB Prophylaxis: O None O INH ASSOCIATED S1 INCREASED TB Treatment: Vone Rifater (Rifampicin / Pyrazinamide / INH) 🗌 Rifafour Ethambutol Streptomycin Ethizide (Ethambutol / INH) Start Date of TB Treatment: Click -> SEXUALLY TRANSMITTED INFECTION THROAT INJECTED Cryptococcus Tx: None Diflucan TYMPANIC MEMBRANE INJECTED Other Drugs: UPPER RESPIRATORY TRACT INFECTION 8. Adherence: URINARY TRACT INFECTION During the last month has the patient missed any medications? Yes Vo ARVs PCP Prophylaxis TB Prophylaxis Anti-TB Medication Drugs Missed: Reason(s): During the last seven days how many of his/her pulls did the patient take? ARVS: None ○ Few ○ Half ○ Most ○ All Drugs Missed: PCP Prophylaxis: None Few Half Most All Drugs Missed: TB Prophylaxis: None Few Half Most All Drugs Missed: Anti-TB Medication: None Few Half Most All Drugs Missed: Cryptococcus Tx: None Few Half Most All Drugs Missed: Reason(s) for missing pills in the last 7 days: 9. Physical Exam: BP: 120 / 80 P: 70 Temp: 37.0 Wt: 60 Height: 172 SaOa: 99 General: 🗌 Jaundice 🗌 Pale 🗹 Adenopathy 🛛 Mucocutaneous: 🗌 Thrush 🔲 Kaposi 🔲 Rash Comments Adult Followup Version 4.1 Draft 24 Feb 05 Next Page -> Form template's location: http://amrs.iukenya.org

Z sample.infopathxml - Microsoft Office InfoPath 2003



Why CDSS can fail in this setting:

- Unreliable generation of summaries & reminders
 - Poor infrastructure: power, printers, viruses.
 - nurses too busy to print summaries.
- Inaccurate reminders
 - Lab results in paper but not in EHRs.
 - Errors on encounter forms, and with data-entry.
 - Delayed data entry.
- Providers ignoring accurate reminders
 - Rote practice patterns or unaware of approved guidelines.

- Noormohammad SF, Mamlin BW, Biondich PG, McKown B, Kimaiyo SN, Were MC. IJMI 2010;79(3):204-10. 50

Clinical Summaries with Reminders

- Clinical summaries with reminders available to >50,000 AMPATH patients (21 sites) at the time of visit.
- Include Adult HIV, Pediatric HIV, and Antenatal Care summaries.
- > 30 Adult and Pediatric reminders currently implemented.
- Work supported by Abbott Fund.





Impact of computer-generated care suggestions on compliance with CD4 testing algorithms



Elements of Quality Care

- Recognize patients at risk for diseases.
- Do appropriate evaluation.
- Make the appropriate diagnosis.
- Start the appropriate treatment.
- Schedule the appropriate follow-up.
- Stimulate the appropriate adherence to treatment.





Elements of Quality Care

- Recognize patients at risk for diseases.
- Do appropriate evaluation.
- Make the appropriate diagnosis.
- Start the appropriate treatment.
- Schedule the appropriate follow-up.
- Stimulate the appropriate adherence to treatment.







Only 12% of men and 10% of women in sub-Saharan Africa know their HIV-status.





- USAID-AMPATH's home visit program:
 - Visit all 2 million individuals in catchment area.
 - Collect basic health information.
 - Offer focused care services.
- Typically, records collected during such visits could have been paper-based.
- Hypothesis:

We can completely leapfrog paper-based records, and create electronic health records (EHRs) for each home-based clinical visit.





- Goals of Home Visits:
 - Identify HIV-positive pts unaware of their status.
 - Offer care services to identify patients as needed.
 - Identify pregnant women not receiving antenatal care.
 - Identify orphaned and vulnerable children.
 - Identify children without appropriate immunizations.
 - Identify individuals at risk for TB.
 - Provide rapid HIV testing.
 - Sputum testing for TB.
 - Provide de-worming medications.
 - Provide bed nets to families.





- Developing Handheld Program:
 - Engaged stakeholders.
 - Identified data elements to be collected.
 - Understood workflow and testing algorithms.





Household Information



Courtesy of USAID/AMPATH. Used with permission.





HIV Module



Courtesy of USAID/AMPATH. Used with permission.



TB Module



Courtesy of USAID/AMPATH. Used with permission.



Palm T X and Garmin e-trex Devices

Photo showing connected devices removed due to copyright restrictions.





Community Mobilization







HCT Counselors







Door-To-Door HCT







HCT Counseling



_DSC6317.JPG Copyright © 2009 Craig Bender Photography





HCT Testing



_DSC6333.JPG Copyright © 2009 Craig Bender Photography





HCT Testing



_DSC6344.JPG Copyright © 2009 Craig Bender Photography





HCT and Handheld Technology







Results:

- Jul-Oct 2008:
 - 93 CHWs visited 14,648 households.
 - 40,111 people (55% female, 26% < 13 years old) had electronic records created.
 - 403 of 899 (45%) pregnant women identified were not receiving antenatal care.
 - 1,131 HIV+ pts identified. 693 (61.3%) were new diagnoses.
 - 376 individuals had been exposed to or had symptoms suggestive of tuberculosis sputum samples collected.





Cost of Technology:

- 2 million tested in 3 yrs (2,565 / day in 780 workdays).
- 320 sets of PDA/GPS devices @ \$573 per set.

ltem	Cost
320 GPS/PDA/Cable Devices/Pendragon Licenses	\$183,360
18 PCs @ \$1,500 each	\$27,000
Programming time 1-month	\$1,500
IT person (50% FTE) for 3 yrs	\$22,000
Data Assistants (2 FTEs) for 3 years	\$45,000
Data Manager (50% FTE) for 3 years	\$22,000
Training on technology for counselors & HCT staff	\$1,000
TOTAL	\$301,860





Cost of Technology:

- With PDA/GPS \$301,860 for 2 million people.
 <u>\$0.15</u> per individual seen or per record created by CHW.
- Compare to:
- Manual data entry:
 - Current pay is \$17 / day to enter ~ 80 encounter forms. **<u>\$0.21</u>** per encounter form entered.





Improving Technology



- Built Open-Source HCT software (ODK).
- Use single device with GPS, bar-coding, and camera.
- HCT data stored in an instance of OpenMRS.
- Providing 'Universal' IDs during HCT.





Nothing is Easy







Bringing Care to Individuals







Improving Access & Awareness







Five-Stage Framework for Evaluation of HIT Projects

- (1) Problem definition.
- (2) Bench testing in the laboratory.
- (3) Early field trials under the direct control of the original investigator.
- (4) Field testing in new or unfamiliar settings.
- (5) Definitive study of the system's efficacy during routine operational use.
- Stead WW, Haynes RB, Fuller S, et al. Designing medical informatics research and library--resource projects to increase what is learned. J Am Med Inform Assoc 1994;1(1):28-33

Thank you.



Australia	Canada	Germany	New Zealand	Britain	United States
3.5	5	2	3.5	1	6
4	6	2.5	2.5	1	5
3	5	1	2	4	6
4	5	3	2	1	6
2	5	4	3	1	6
1	3	2	4.5	4.5	6
\$2,876*	\$3,165	\$3,005*	\$2,083	\$2,546	\$6,102
	3.5 4 3 4 2 1	3.5 5 4 6 3 5 4 5 2 5 1 3	4 6 2.5 3 5 1 4 5 3 2 5 4 1 3 2	AustraliaCanadaGermanyZealand3.5523.5462.52.53512453225431324.5	AustraliaCanadaGermany ZealandZealandBritain Zealand3.5523.51462.52.513512445321254311324.54.5

Image by MIT OpenCourseWare. Source: The Commonwealth Fund. * 2003 data.



Masaka Clinic

- Funded by Uganda National AIDS control Program
- 5,100 HIV +ve patients
- Care by MDs, Nurse Practitioners and Clinical Officers (CO).
- Hand-written free-text paper records
- No patient scheduling system

Mbarara Clinic

- Funded by Uganda National AIDS control Program
- 11,000 HIV +ve patients
- Care by MDs only.
- Structured paper-based encounter forms with coded answers used
- No patient scheduling system

HST.S14 Health Information Systems to Improve Quality of Care in Resource-Poor Settings Spring 2012

For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.